Fatty Liver Disease -- It's More Than Alcohol and Obesity

Heiner Wedemeyer, MD, Michael P. Manns, MD


July 23, 2003

In This Article

Concluding Remarks

Our understanding of the pathogenetic mechanisms underlying NAFLD and NASH has increased significantly in recent years. Several new therapeutic options are on the horizon; however, randomized multicenter trials are still lacking for most of these agents. It is hoped that within the next few years we will have evidence-based treatment guidelines combining well-tolerated lifestyle modifications with new drugs to help prevent progression of fibrosis in patients with NAFLD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: